The COVID Moonshot is a highly accelerated discovery project aiming to identify an orally available treatment for COVID-19. In order to perform all preclinical activities required to enable Phase I studies, DNDi is now sourcing a Contract Research Organization (CRO) offering an integrated platform capable of delivering the nonclinical safety and toxicology aspects of the project.

The COVID Moonshot is a highly accelerated discovery project aiming to identify an orally available treatment for COVID-19. In order to perform all preclinical activities required to enable Phase I studies, DNDi is now sourcing a Contract Development and Manufacturing Organization (CDMO) offering process research and manufacturing capabilities to provide drug substance API for use in Phase I clinical trials.

The COVID Moonshot is a highly accelerated discovery project aiming to identify an orally available treatment for COVID-19. In order to perform all preclinical activities required to enable Phase I studies, DNDi is now sourcing a Contract Development and Manufacturing Organization (CDMO) offering pharmaceutical development capabilities to provide preclinical formulation support as well as drug product production and batch release ready for Phase I activities.

DNDi is sourcing a CDMO for formulation activities leading to commercialisable tablet formulation, followed by GMP manufacturing and packaging of clinical supplies to support the Phase Ib and II trials targeting visceral leishmaniasis.

DNDi is sourcing a CRO offering Data Management, Biostatistics, and IRT Services for one of our clinical trial targeting visceral leishmaniasis.

DNDi is currently sourcing a CRO able to perform a CTA enabling package for one compound targeting visceral leishmaniasis.

DNDi is seeking a CDMO/partner to play a major role in improving the API process of a novel DNDi compound that will enable the realization of low production costs.

DNDi is sourcing a Contract Development and Manufacturing Organization (CDMO) offering an integrated platform of pharmaceutical development and manufacturing capabilities to cover Drug Substance and Drug Product activities of a compound targeting onchocerciasis.